Tofacitinib 5 mg twice daily (DrugBank: Tofacitinib)
12 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
11 | 重症筋無力症 | 0 |
40 | 高安動脈炎 | 0 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 0 |
50 | 皮膚筋炎/多発性筋炎 | 0 |
51 | 全身性強皮症 | 0 |
53 | シェーグレン症候群 | 0 |
84 | サルコイドーシス | 1 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
107 | 若年性特発性関節炎[全身型若年性特発性関節炎(~2018.3)] | 0 |
271 | 強直性脊椎炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03910543 (ClinicalTrials.gov) | April 11, 2019 | 4/4/2019 | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Cutaneous Sarcoidosis;Granuloma Annulare | Drug: Tofacitinib 5 mg twice daily | Yale University | Pfizer | Active, not recruiting | 18 Years | N/A | All | 15 | Phase 1 | United States |